Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus ...
This appointment reflects a shared mission with Lucid Group to transform lives by ensuring innovative medicine doesn't stop at approval but reaches the patients who need it most. His leadership marks ...
The MarketWatch News Department was not involved in the creation of this content. -- Focused Execution Drives Strong Full-Year 2025 EPS Performance -- Enters 2026 with Clear Strategic Priorities and ...
Zacks Investment Research on MSN
Pfizer (PFE) down 0.6% since last earnings report: Can it rebound?
It has been about a month since the last earnings report for Pfizer (PFE). Shares have lost about 0.6% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the ...
(NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its primary efficacy ...
The announcement Monday from Pfizer and its German partner BioNTech that their coronavirus vaccine appears to be 90% effective thrilled medical experts around the world and presented a glimmer of hope ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results